Compare EGY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | CSTL |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.2M | 722.8M |
| IPO Year | 1996 | 2019 |
| Metric | EGY | CSTL |
|---|---|---|
| Price | $6.28 | $32.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.20 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 1.1M | 333.4K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $359,272,000.00 | $344,229,000.00 |
| Revenue This Year | $24.31 | $8.49 |
| Revenue Next Year | $14.62 | $10.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $3.36 | $17.72 |
| 52 Week High | $6.72 | $44.28 |
| Indicator | EGY | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 43.03 |
| Support Level | $5.02 | $31.44 |
| Resistance Level | $6.67 | $34.23 |
| Average True Range (ATR) | 0.17 | 1.75 |
| MACD | 0.04 | -0.40 |
| Stochastic Oscillator | 94.33 | 7.44 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.